English

GOTHENBURG, Sweden, November 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the investigator-initiated Modelle study, evaluating the effect of the drug candidate arfolitixorin at tissue level, has been published in the scientific journal BJC Reports. The information in the press release is intended for investors. Modelle is an investigator-initiated study […]

GOTHENBURG, Sweden, November 20, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), will provide an operational update during today’s investor meeting. The company will present its evidence platform that forms the basis for the upcoming clinical study with drug candidate arfolitixorin, the intended study design for the phase Ib/II study, as well an update

GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that an abstract with results from a post hoc-analysis of the company’s Phase III-study AGENT has been accepted by ASCO GI, which takes place in San Francisco, US, between January 23-25th, 2025. The information in the press release is intended

GOTHENBURG, SWEDEN, October 23, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that a Late Breaking Abstract concerning the drug candidate arfolitixorin is presented as a poster at ENA 2024 in Barcelona, Spain, during October 23-25th 2024. The poster describes a dose-dependent cytotoxic effect and increased activity of arfolitixorin at higher doses